Tarsus Pharmaceuticals, Inc. TARS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $162.05M+6.8% | $151.67M+27.8% | $118.7M+15.6% | $102.66M+31.1% | $78.34M+18.0% | ||
| $9.4M— | —— | —— | —— | $5.21M— | ||
| $152.66M— | —— | —— | —— | $73.12M— | ||
| 94.2%— | —— | —— | —— | 93.3%— | ||
| $22.35M+23.9% | $18.04M+10.8% | $16.28M+4.4% | $15.59M+8.2% | $14.41M-14.6% | ||
| $136.43M+4.4% | $130.68M+20.3% | $108.63M+5.5% | $103.01M+21.2% | $85M+23.1% | ||
| $168.18M+5.3% | $159.64M+19.8% | $133.23M+6.7% | $124.84M+19.3% | $104.62M+15.2% | ||
| -$6.12M+23.2% | -$7.98M+45.1% | -$14.53M+34.5% | -$22.18M+15.6% | -$26.28M-7.6% | ||
| -3.8%+1.5pp | -5.3%+7.0pp | -12.2%+9.4pp | -21.6%+11.9pp | -33.5%+3.2pp | ||
| $2.13M-3.9% | $2.21M-2.4% | $2.27M+1.3% | $2.24M+1.2% | $2.21M-4.3% | ||
| $1.51M-9.3% | $1.66M-14.5% | $1.94M+5.4% | $1.84M+59.0% | $1.16M-11.3% | ||
| —— | -$16.09M0.0% | -$16.09M0.0% | -$16.09M0.0% | -$16.09M+44.3% | ||
| $2.35M— | —— | —— | —— | $0— | ||
| -$6.97M+16.8% | -$8.37M+33.5% | -$12.59M+38.1% | -$20.34M+19.0% | -$25.12M-8.7% | ||
| -4.3%+1.2pp | -5.5%+5.1pp | -10.6%+9.2pp | -19.8%+12.3pp | -32.1%+2.7pp | ||
| -$0.16+15.8% | -$0.19+36.7% | -$0.30+37.5% | -$0.48+25.0% | -$0.64-8.5% | ||
| -$5.69M+24.5% | -$7.53M+46.7% | -$14.13M+35.1% | -$21.78M+15.6% | -$25.82M-7.6% | ||
| -3.5%+1.5pp | -5%+6.9pp | -11.9%+9.3pp | -21.2%+11.7pp | -33%+3.2pp | ||
| -$6.12M+23.2% | -$7.98M+45.1% | -$14.53M+34.5% | -$22.18M+15.6% | -$26.28M-7.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s revenue?
- Tarsus Pharmaceuticals, Inc. (TARS) generated $535.1M in revenue over the trailing twelve months, up 129.0% year over year.
- Is Tarsus Pharmaceuticals, Inc. profitable?
- Tarsus Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $48.3M over the trailing twelve months, a -9.0% net margin.
- What are Tarsus Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 42.7% and operating margin is -9.5%, with a -9.0% net margin.
- What is Tarsus Pharmaceuticals, Inc.'s earnings per share?
- Tarsus Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.13.
- Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
